Burkehill Global Management, LP
Position in DNLI — Denali Therapeutics Inc.
CIK 1904549
NEW YORK, NY
Position in DNLI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$5,144,000
+$1,304,000 QoQ
Shares Held
200,000
0.0% QoQ
Ownership
0.125%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
#62
of 290 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Burkehill Global Management, LP holds $231,675,092 across 66 Biotechnology names. DNLI ranks #14 (2.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TRVI |
Trevi Therapeutics, Inc.
|
725,000 | $13,521,250 | |
| 2 | COGT |
Cogent Biosciences, Inc.
|
325,000 | $12,577,500 | |
| 3 | PRAX |
Praxis Precision Medicines, Inc.
|
35,000 | $11,717,650 | |
| 4 | RAPP |
Rapport Therapeutics, Inc.
|
250,000 | $10,417,500 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
50,000 | $9,364,000 | |
| 6 | KYMR |
Kymera Therapeutics, Inc.
|
75,000 | $8,600,250 | |
| 7 | CYTK |
Cytokinetics Inc
|
100,000 | $8,519,000 | |
| 8 | IDYA |
IDEAYA Biosciences, Inc.
|
200,000 | $7,454,000 |
All Filings in DNLI
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,144,000 | 200,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $3,840,000 | 200,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,302,000 | 200,000 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||